CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 118 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,250,964 | +11.9% | 83,901 | -17.9% | 0.00% | 0.0% |
| Q2 2023 | $1,118,356 | +36.6% | 102,133 | +8.8% | 0.00% | 0.0% |
| Q1 2023 | $818,651 | +1202.2% | 93,882 | +836.3% | 0.00% | – |
| Q4 2022 | $62,869 | +3.1% | 10,027 | -42.7% | 0.00% | – |
| Q3 2022 | $61,000 | +74.3% | 17,495 | +70.3% | 0.00% | – |
| Q4 2021 | $35,000 | -31.4% | 10,273 | -26.6% | 0.00% | – |
| Q3 2021 | $51,000 | -72.9% | 13,995 | -67.5% | 0.00% | -100.0% |
| Q2 2021 | $188,000 | -36.1% | 43,127 | -33.3% | 0.00% | -50.0% |
| Q1 2021 | $294,000 | -66.7% | 64,671 | -57.9% | 0.00% | -71.4% |
| Q4 2020 | $882,000 | +132.1% | 153,593 | +192.6% | 0.01% | +40.0% |
| Q3 2020 | $380,000 | -60.1% | 52,501 | -80.8% | 0.01% | -66.7% |
| Q2 2020 | $953,000 | +258.3% | 273,172 | +52.1% | 0.02% | +114.3% |
| Q1 2020 | $266,000 | +10.8% | 179,573 | +46.6% | 0.01% | +600.0% |
| Q4 2019 | $240,000 | -86.4% | 122,532 | -64.5% | 0.00% | -93.8% |
| Q3 2019 | $1,765,000 | +194.2% | 344,735 | +662.8% | 0.02% | +166.7% |
| Q1 2019 | $600,000 | +103.4% | 45,195 | +23.6% | 0.01% | 0.0% |
| Q3 2017 | $295,000 | +186.4% | 36,570 | +105.4% | 0.01% | +200.0% |
| Q2 2017 | $103,000 | -22.6% | 17,800 | -42.6% | 0.00% | -50.0% |
| Q1 2017 | $133,000 | – | 31,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |